Loading...
•
Sep 30, 2025
cbdMD Q4 2025 Earnings Report
cbdMD reported its Q4 2025 results with modest revenue growth and reduced quarterly losses, reflecting continued cost control and operational improvements.
Key Takeaways
cbdMD saw Q4 revenue increase slightly while cutting operating and net losses, aided by disciplined cost management. The company ended the year with improved margins and a strengthened balance sheet.
Q4 revenue reached $4.72 million, up from $4.56 million the year prior
Q4 net loss narrowed to $2.04 million from $3.7 million in Q4 2024
Adjusted operating loss improved to $301,496 in Q4 versus $131,009 in the prior year
Cash on hand at year-end was $2.26 million with improved working capital
Revenue by Segment
Forward Guidance
The company enters calendar 2026 with improved financial flexibility and aims to continue focusing on quality, science, and responsible growth amid evolving federal cannabinoid policy.
Positive Outlook
- Improved balance sheet with $2.25M in new equity raised
- Operational improvement sustained for the third consecutive year
- Expanded Herbal Oasis distribution across six U.S. states
- Regained NYSE American listing compliance
- Positioned for regulatory tailwinds related to cannabinoid policy reform
Challenges Ahead
- Continued net losses impacting overall profitability
- Ongoing going-concern audit warning in FY25 filing
- Revenue remains flat compared to prior year
- DTC revenue declined by 6% YoY
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...